Wuxi PharmaTech, China’s largest pharmaceutical and biotechnology research and development outsourcing company, said Monday it will spend between US$41.68 million and US$55.58 million (RMB300-RMB400 million) upgrading its research and production facilities this year, the Shanghai Business Journal reported. The planned expenditure is between 50% and 100% greater than the year before. The Shanghai-based, ...